Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
In their 4Q25 commentary, Conestoga Capital Advisors reported performance underperformance across most strategies against their growth benchmarks due to a highly concentrated, 'low-quality' rally dominated by unprofitable, high-beta names (particularly biotech and AI hardware). The manager provides...
— Joe Monahan
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Repligen
Repligen Corporation is positioned to benefit from numerous company-specific tailwinds in 2025, making it a compelling investment in the bioprocessing space. Despite...
Repligen Corporation recently announced a strategic acquisition of BioLife Solutions to expand its capabilities in the cell therapy market. The deal, valued...